<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1008">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501952</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-540-9012</org_study_id>
    <secondary_id>2020-003510-12</secondary_id>
    <nct_id>NCT04501952</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in
      reducing the rate of hospitalization or death in non-hospitalized participants with early
      stage coronavirus disease 2019 (COVID-19) and to evaluate the safety of RDV administered in
      an outpatient setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint Measuring Proportion of Participants Hospitalized or Death From Any Cause by Day 14.</measure>
    <time_frame>From date of randomization up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>From date of randomization up to 3 days plus 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hospitalization by Day 28</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load from Baseline to Day 7</measure>
    <time_frame>Baseline; Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of COVID-19-Related Symptoms</measure>
    <time_frame>First Dose Date Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Progressing to Requiring Oxygen Supplementation by Day 28</measure>
    <time_frame>From date of randomization up to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1230</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Remdesivir (RDV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDV</intervention_name>
    <description>Administered as an intravenous infusion</description>
    <arm_group_label>Remdesivir (RDV)</arm_group_label>
    <other_name>GS-5734™</other_name>
    <other_name>Veklury®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Match RDV</intervention_name>
    <description>Administered as an intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent, or with a legal representative
             who can provide informed consent (individuals ≥ 18 years of age) or assent
             (individuals ≥ 12 and &lt; 18 years of age) prior to performing study procedures. For
             individuals ≥ 12 and &lt; 18 years of age, a parent or legal guardian must be willing and
             able to provide written informed consent prior to performing study procedures

          -  Either:

               -  Age ≥ 18 years (at all sites) or aged ≥ 12 and &lt; 18 years of age weighing ≥ 40 kg
                  (where permitted according to local law and approved nationally and by the
                  relevant institutional review board (IRB) or independent ethics committee (IEC)
                  with at least 1 pre-existing risk factor for progression to hospitalization
                  (chronic lung disease, hypertension, cardiovascular or cerebrovascular disease,
                  diabetes, obesity (body mass index ≥ 30), immunocompromised, chronic mild or
                  moderate kidney disease, chronic liver disease, current cancer, or sickle cell
                  disease)

               -  OR aged ≥ 60 years

          -  SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) ≤ 4 days prior to
             screening

          -  Presence of ≥ 1 symptom(s) consistent with COVID-19 for ≤ 7 days prior to
             randomization

          -  Oxygen saturation (SpO2) &gt; 94% on room air

          -  Not currently requiring hospitalization

        Key Exclusion Criteria:

          -  Participation in any other clinical trial of an experimental treatment and prevention
             for COVID-19

          -  Prior hospitalization for COVID-19

          -  Treatment with other agents with actual or possible direct antiviral activity against
             SARS-CoV-2

          -  Use of hydroxychloroquine or chloroquine ≤ 7 days prior to screening

          -  Requiring oxygen supplementation

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Midland Florida Clinical Research Center, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lawnwood Regional Medical Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AIDS Research and Treatment Center of the Treasure Coast</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agile Clinical Research Trials</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Trials</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Gulfport</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rosedale Infectious Diseases</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

